FI2981272T3 - Mikrohuokoinen zirkoniumsilikaatti ja diureetteja kaliumin vähentämiseksi ja kroonisen munuais- ja/tai kroonisen sydänsairauden hoitamiseksi - Google Patents
Mikrohuokoinen zirkoniumsilikaatti ja diureetteja kaliumin vähentämiseksi ja kroonisen munuais- ja/tai kroonisen sydänsairauden hoitamiseksi Download PDFInfo
- Publication number
- FI2981272T3 FI2981272T3 FIEP14779186.7T FI14779186T FI2981272T3 FI 2981272 T3 FI2981272 T3 FI 2981272T3 FI 14779186 T FI14779186 T FI 14779186T FI 2981272 T3 FI2981272 T3 FI 2981272T3
- Authority
- FI
- Finland
- Prior art keywords
- zirconium silicate
- diuretic
- use according
- ion
- potassium
- Prior art date
Links
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 title claims 22
- 239000002934 diuretic Substances 0.000 title claims 15
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims 2
- 229910052700 potassium Inorganic materials 0.000 title claims 2
- 239000011591 potassium Substances 0.000 title claims 2
- 230000001684 chronic effect Effects 0.000 title 2
- 229940030606 diuretics Drugs 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 229940097420 Diuretic Drugs 0.000 claims 14
- 230000001882 diuretic effect Effects 0.000 claims 14
- 239000013078 crystal Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000002441 X-ray diffraction Methods 0.000 claims 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims 1
- KXDROGADUISDGY-UHFFFAOYSA-N Benzamil hydrochloride Chemical compound C=1C=CC=CC=1CN=C(N)NC(=O)C1=NC(Cl)=C(N)N=C1N KXDROGADUISDGY-UHFFFAOYSA-N 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- 229940122767 Potassium sparing diuretic Drugs 0.000 claims 1
- 229910052777 Praseodymium Inorganic materials 0.000 claims 1
- 229910000577 Silicon-germanium Inorganic materials 0.000 claims 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 claims 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims 1
- 229960002576 amiloride Drugs 0.000 claims 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 1
- NCMHKCKGHRPLCM-UHFFFAOYSA-N caesium(1+) Chemical compound [Cs+] NCMHKCKGHRPLCM-UHFFFAOYSA-N 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 229960005057 canrenone Drugs 0.000 claims 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 claims 1
- ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical compound [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 claims 1
- 229960001208 eplerenone Drugs 0.000 claims 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 1
- CULSIAXQVSZNSV-UHFFFAOYSA-N germanium(4+) Chemical compound [Ge+4] CULSIAXQVSZNSV-UHFFFAOYSA-N 0.000 claims 1
- GVOLZAKHRKGRRM-UHFFFAOYSA-N hafnium(4+) Chemical compound [Hf+4] GVOLZAKHRKGRRM-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002171 loop diuretic Substances 0.000 claims 1
- 229910001425 magnesium ion Inorganic materials 0.000 claims 1
- 229910052758 niobium Inorganic materials 0.000 claims 1
- 239000010955 niobium Substances 0.000 claims 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 claims 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 claims 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims 1
- 229910001419 rubidium ion Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 claims 1
- 229960002256 spironolactone Drugs 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- NTRPDBRJGBMHQP-UHFFFAOYSA-N terbium(4+) Chemical compound [Tb+4] NTRPDBRJGBMHQP-UHFFFAOYSA-N 0.000 claims 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 claims 1
- 229960001288 triamterene Drugs 0.000 claims 1
- 229910052726 zirconium Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Geology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808897P | 2013-04-05 | 2013-04-05 | |
| US201361914362P | 2013-12-10 | 2013-12-10 | |
| US201461930331P | 2014-01-22 | 2014-01-22 | |
| PCT/US2014/032815 WO2014165670A1 (en) | 2013-04-05 | 2014-04-03 | Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI2981272T3 true FI2981272T3 (fi) | 2023-05-03 |
Family
ID=51654632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP14779186.7T FI2981272T3 (fi) | 2013-04-05 | 2014-04-03 | Mikrohuokoinen zirkoniumsilikaatti ja diureetteja kaliumin vähentämiseksi ja kroonisen munuais- ja/tai kroonisen sydänsairauden hoitamiseksi |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20140302175A1 (enExample) |
| EP (1) | EP2981272B1 (enExample) |
| JP (1) | JP6280636B2 (enExample) |
| KR (1) | KR102308673B1 (enExample) |
| CN (1) | CN105473151B (enExample) |
| AU (1) | AU2014248081B2 (enExample) |
| BR (1) | BR112015025438B1 (enExample) |
| CA (1) | CA2908641C (enExample) |
| CL (1) | CL2015002951A1 (enExample) |
| DK (1) | DK2981272T3 (enExample) |
| ES (1) | ES2943007T3 (enExample) |
| FI (1) | FI2981272T3 (enExample) |
| HU (1) | HUE061862T2 (enExample) |
| IL (1) | IL241926B (enExample) |
| MX (1) | MX2015014055A (enExample) |
| PH (1) | PH12015502301A1 (enExample) |
| PL (1) | PL2981272T3 (enExample) |
| PT (1) | PT2981272T (enExample) |
| TW (1) | TW201521746A (enExample) |
| WO (1) | WO2014165670A1 (enExample) |
| ZA (1) | ZA201507666B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900037T1 (it) | 2011-02-11 | 2019-02-28 | Zs Pharma Inc | Uso di un silicato di zirconio per il trattamento di iperkaliemia |
| US9592253B1 (en) | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
| CN114917247B (zh) * | 2022-05-18 | 2024-01-26 | 广东省疾病预防控制中心 | 纳米二氧化钛在防治肾损伤中的应用 |
| CN117776193A (zh) * | 2023-12-25 | 2024-03-29 | 杭州国瑞生物科技有限公司 | 一种环硅酸锆钠zs-9的制备方法及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9601398D0 (en) * | 1996-01-24 | 1996-03-27 | Piper Edwina M | Composition |
| US5891417A (en) | 1997-04-08 | 1999-04-06 | Uop Llc | Zirconium silicate and zirconium germanate molecular sieves and process using the same |
| US5888472A (en) | 1997-04-08 | 1999-03-30 | Uop Llc | Zirconium silicate molecular sieves and process using the same |
| US6099737A (en) | 1999-03-29 | 2000-08-08 | Uop Llc | Process for removing toxins from blood using zirconium metallate or titanium metallate compositions |
| US6332985B1 (en) | 1999-03-29 | 2001-12-25 | Uop Llc | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
| EP1307270A1 (en) * | 2000-07-12 | 2003-05-07 | Uop Llc | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
| AU2002242103A1 (en) * | 2001-02-06 | 2002-08-19 | Ash Medical Systems, Inc. | Monovalent-selective cation exchangers as oral sorbent therapy |
| US6579460B1 (en) * | 2001-03-13 | 2003-06-17 | Uop Llc | Process and composition for removing toxins from bodily fluids |
| WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| CN103919792B (zh) | 2008-08-22 | 2018-03-09 | 瑞立普萨公司 | 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用 |
| US20120070468A1 (en) * | 2010-09-16 | 2012-03-22 | Uop Llc | Removal of toxins from gastrointestinal fluids |
| SMT201900037T1 (it) * | 2011-02-11 | 2019-02-28 | Zs Pharma Inc | Uso di un silicato di zirconio per il trattamento di iperkaliemia |
| MX2015000381A (es) * | 2012-07-11 | 2015-11-23 | Zs Pharma Inc | Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia. |
| KR102184602B1 (ko) * | 2012-10-22 | 2020-11-30 | 제트에스 파마, 인코포레이티드 | 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트 |
-
2014
- 2014-04-03 CA CA2908641A patent/CA2908641C/en active Active
- 2014-04-03 KR KR1020157031787A patent/KR102308673B1/ko active Active
- 2014-04-03 HU HUE14779186A patent/HUE061862T2/hu unknown
- 2014-04-03 ES ES14779186T patent/ES2943007T3/es active Active
- 2014-04-03 CN CN201480032064.8A patent/CN105473151B/zh active Active
- 2014-04-03 US US14/244,446 patent/US20140302175A1/en not_active Abandoned
- 2014-04-03 PL PL14779186.7T patent/PL2981272T3/pl unknown
- 2014-04-03 PT PT147791867T patent/PT2981272T/pt unknown
- 2014-04-03 BR BR112015025438-1A patent/BR112015025438B1/pt active IP Right Grant
- 2014-04-03 FI FIEP14779186.7T patent/FI2981272T3/fi active
- 2014-04-03 JP JP2016506615A patent/JP6280636B2/ja active Active
- 2014-04-03 MX MX2015014055A patent/MX2015014055A/es unknown
- 2014-04-03 US US14/782,288 patent/US20160051584A1/en not_active Abandoned
- 2014-04-03 DK DK14779186.7T patent/DK2981272T3/da active
- 2014-04-03 AU AU2014248081A patent/AU2014248081B2/en active Active
- 2014-04-03 EP EP14779186.7A patent/EP2981272B1/en not_active Revoked
- 2014-04-03 WO PCT/US2014/032815 patent/WO2014165670A1/en not_active Ceased
- 2014-04-07 TW TW103112757A patent/TW201521746A/zh unknown
-
2015
- 2015-10-02 CL CL2015002951A patent/CL2015002951A1/es unknown
- 2015-10-05 PH PH12015502301A patent/PH12015502301A1/en unknown
- 2015-10-06 IL IL241926A patent/IL241926B/en active IP Right Grant
- 2015-10-14 ZA ZA2015/07666A patent/ZA201507666B/en unknown
-
2018
- 2018-03-19 US US15/925,348 patent/US10695366B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6280636B2 (ja) | 2018-02-14 |
| CA2908641C (en) | 2022-10-18 |
| EP2981272A1 (en) | 2016-02-10 |
| IL241926B (en) | 2020-10-29 |
| AU2014248081B2 (en) | 2019-02-28 |
| MX2015014055A (es) | 2015-12-15 |
| CL2015002951A1 (es) | 2016-11-11 |
| HUE061862T2 (hu) | 2023-08-28 |
| EP2981272A4 (en) | 2016-12-07 |
| WO2014165670A1 (en) | 2014-10-09 |
| EP2981272B1 (en) | 2023-03-01 |
| KR20150140750A (ko) | 2015-12-16 |
| US20140302175A1 (en) | 2014-10-09 |
| CN105473151B (zh) | 2018-09-18 |
| DK2981272T3 (da) | 2023-05-01 |
| US10695366B2 (en) | 2020-06-30 |
| BR112015025438B1 (pt) | 2022-06-07 |
| JP2016515624A (ja) | 2016-05-30 |
| HK1221177A1 (en) | 2017-05-26 |
| AU2014248081A1 (en) | 2015-11-12 |
| PH12015502301A1 (en) | 2016-02-10 |
| US20180271902A1 (en) | 2018-09-27 |
| ES2943007T3 (es) | 2023-06-08 |
| KR102308673B1 (ko) | 2021-10-01 |
| CN105473151A (zh) | 2016-04-06 |
| CA2908641A1 (en) | 2014-10-09 |
| PL2981272T3 (pl) | 2023-05-29 |
| ZA201507666B (en) | 2019-09-25 |
| PT2981272T (pt) | 2023-05-03 |
| BR112015025438A2 (pt) | 2017-07-18 |
| TW201521746A (zh) | 2015-06-16 |
| US20160051584A1 (en) | 2016-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190146T4 (hr) | Uporaba cirkonijevog silikata za liječenje hiperkalemije | |
| FI2981272T3 (fi) | Mikrohuokoinen zirkoniumsilikaatti ja diureetteja kaliumin vähentämiseksi ja kroonisen munuais- ja/tai kroonisen sydänsairauden hoitamiseksi | |
| FI2882444T3 (fi) | Mikrohuokoinen zirkoniumsilikaatti hyperkalemian hoitoon | |
| CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| JP2016065086A5 (enExample) | ||
| JP2014114295A5 (enExample) | ||
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| WO2013032744A3 (en) | Compositions and methods for increasing desirable microbiota | |
| JP2011126917A5 (enExample) | ||
| FI4321157T3 (fi) | Angiotensiinireseptorin salpaajan (arb) ja neutraalin endopeptidaasin estäjän (nepi) yhdistelmän uusi käyttötapa | |
| JP2012502909A5 (enExample) | ||
| ZA202400795B (en) | Nitrosamine impurity, varenicline pharmaceutical composition capable of reducing generation of nitrosamine impurities and preparation and use thereof | |
| JP2016530291A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| JP2016515624A5 (enExample) | ||
| MY200278A (en) | Methods of improving exercise capacity in fontan patients using udenafil compositions | |
| NZ758513A (en) | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | |
| PH12015501301B1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| CA3088596C (en) | CRYSTALLINE FORM OF SODIUM BICTEGRAVIR | |
| Laranjinha et al. | Magnesium supplementation to prevent recurrence of renal stones | |
| WO2012013756A3 (fr) | Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol | |
| JP2011026313A5 (ja) | 糖代謝改善剤 | |
| CN106176989A (zh) | 一种治肺脓疡的配方 | |
| TN2014000106A1 (en) | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |